163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study

A.T.C. Chan, H.F.V. Lee,R-L. Hong,M-J. Ahn, W.Q. Chong,S-B. Kim,H.G. Fuang, P.B. Caguioa, N. Ngamphaiboon,C. Ho,M.A.S. Abdul Aziz, Q.S. Ng,C.J. Yen,N. Soparattanapaisarn, R. Ngan, S.K. Kho, L. Wang,R. Swaby,S. Saraf, L.L. Siu

Annals of Oncology（2021）

引用 0|浏览3

暂无评分

摘要

Pembro did not improve OS vs chemo in patients (pts) with platinum-pretreated R/M NPC in KEYNOTE-122 (NCT02611960), but it had manageable safety and fewer treatment-related AEs. HRQoL results are shown.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要